Angelini Pharma announced on Thursday that it will acquire Catalyst Pharmaceuticals in a $4.1 billion deal, marking the Italian drugmaker’s entry into the U.S. pharmaceutical market.
Under the terms of the agreement, Angelini will pay $31.50 in cash for each Catalyst share, representing a premium of about 3% over the company’s previous closing price.
Read Also – Global operation against illicit pharmaceuticals results in $15.5 million worth of seizures
The acquisition will be backed by funds managed by Blackstone along with selected international partners, while BNP Paribas will act as the global coordinator and underwriter for the deal.
Founded in 2002, Florida-based Catalyst Pharmaceuticals focuses on developing treatments for rare and hard-to-treat medical conditions. The company’s U.S.-listed shares have risen more than 30% this year, giving it a market valuation of approximately $3.73 billion, according to market data.
The acquisition will establish Angelini Pharma as a “relevant global player in neurological rare diseases,” CEO Sergio Marullo di Condojanni said, adding that entering the U.S. market will help the drugmaker expand its scale and capabilities.
Angelini Pharma is the pharmaceutical arm of Italy-based privately held Angelini Industries
, whose operations span healthcare, consumer goods, and industrial technology sectors.
The group operates in 21 countries and generated annual revenue of 1.6 billion euros ($1.88 billion) in 2024, driven mainly by the strong performance of its healthcare business.
